Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed that the $150M MC (~$1.07 SP) is a good consolidation point. I see IPIX to have at least a $200M MC (~$1.43 SP) if B-OM is successful. Will Leo give us a really happy Friday tomorrow?
Dud thinks everybody is selling shares. Including him.
Pete - Like that theory !!!
More BS. Management has to file Form 4 if they sold today.
yes,that's correct..
it would 'amount to buying back some shares I sold the other day'
it was for me, good money management,playing the odds, etc.
93 cents now, is not the same "93" as it was a week ago. It was a resistance target last week and its a support target now.
I also hope nobody makes decisions based on just my TA, or anyone else's.
If there might be a little dip to start tomorrow, could become the last dip to buy here before news comes.
just for giggles, I'll bet we get a little plunge at the open. maybe hits 95.
I would love to see an after hours announcement so that a major buildup could come about. Why not do it tomorrow at close so that the entire weekend could be a pressure cooker for those wanting to get in?
Sure would make Monday an exciting day! Take the traders by surprise and the shorters as well. Reward those who have already placed their bets on the company.
I'm in for more tomorrow/Monday on any pullback.
A stink bid for what, to buy back the 1000 shares that you sold other day?!? Ha. Come on, your technical analysis commentary is getting redundant. Sure, it could go down tomorrow anyone can guess that. But chances are that hesitant investors and people reading this board are gonna miss the boat when they wake up to a press release that causes a 50-100% pop when the market opens.
And you’re excited about saving $80-$100 bucks on your next share purchase! Funny stuff Tommy??.
Anyways, I just hope people aren’t waiting to get in at lower prices with your TA. Because they are going to be kicking themselves for not grabbing the bull by the horns...
Go IPIX
GO LEO! Release the Kraken!
PS. I just convinced myself to add tomorrow! Treasure chest of IPIX shares is getting pretty damn heavy!
Watch Clay Traders video. He is very bullish and stated today’s action was better than another move up.
Yes. Great point.
Aspire made it possible for the company to purchase the Brilacidin platform in addition to running clinical trials. That purchase was brilliant.
Also, management isn't selling, unless they have a deal with a bp we aren't aware of yet.
What a crock. Management is not selling unless
we have Possible deal very soon.
Wrong dud. Aspire only funds this company and has funded this company through several positive trials. Aspire made it possible for IPIX to succeed in spite of the plethora of negative attacks.
Spot on with what?
"That it won't happen at all?" good choice.
Aspire's capital infusions were needed but it would sure be nice for a BP clinical partner to step up with a nondilutive cash infusion and sponsor a couple of PIII trials so shareholders can see some price appreciation.
I think you are spot on. Aspire and mgmt were likely the heavy sellers today
I'm ready with stink bids for tomorrow's open...
just in case.
Todays little slide down to 1.04 has that funny look to me.
what's a good target for one nice plunge...
10 cents down/12 cents down ? something like 92-94 maybe?
90? don't want to be greedy here,but I also like 88.
or it might not happen at all. Maybe it bounces up from here or 1 dollar.
(oops, sorry 'infinity', didn't mean to post on top of yours) meant a new msg.
* * $IPIX Video Chart 12-07-17 * *
Link to Video - click here to watch the technical chart video
glass half full assessment, and I hope you are right
glass half empty: they added sites because they wanted to get the trail finished. Leo said "early" because he was well aware from P2a that P showed benefit early in some cases. Commanding significant market value- heck, anybody would say that.
Aspire is making this company flower. Aspire makes more money when the stock goes up.
Do some DD on it.
What hasn't been shown is trading over the 200 MDA. This is a first at least this year. It's easy to say the stock is going back to touch the 200 MDA. But I don't believe so. I think it will at least trade somewhat sideways and let the 200 MDA catch it.
It could happen if there is a significant drop in volume and the results don't come out tomorrow or next week.
But I am banking we stay above 1.00 until results are out.
.60's/.70's to over the $ in just a matter of days earns some decent consolidation.
That simple.
Once we do get data? We'll be moving in bigger chunks. Up up and away!!
$IPIX
We'll be cutting resistance like a hot knife through butter.
cup & handle is beginning to take place. you chance to buy back in is shorter and shorter. I hope this time it shoots up to $10 overnight. GL to all longs.
No! The story is fundamentally different today, with positive clinical trial data expected to be released within just days. The company is in a totally different place than it was in March. Your comparison is simply specious.
This company is not a "PIG"! It's a pre-clinical biotech with three separate drug platforms, all in various stages of clinical trial, with positive results expected to be released at any time!
DOTB
WRONG! This stock is NOT A "PIG"!!! And Aspire is not a villain!
It's Aspire that's made shareholder wealth possible! All pre-revenue biotech companies have to get funding from somewhere, and IPIX's deal with Aspire has been an excellent choice. Without funding IPIX would not have been able to afford the platform development and clinical trials that make it the company on the threshold of greatness that it is today.
After several days of strength ahead of clinical trial results, IPIX today closed flat on great volume. This is normal and healthy. We all wait release of trial data, expected in just days. There's no legitimate way to cast the past week's price action, or today's, as anything but stellar.
DOTB
Looks like volume of 561,000 is it for today.
Back again tomorrow.
Echo20
Data for Brilacidin can come at any moment. Leo won't sit on it.
Good call NR. I do remember that post now. 1.17 yesterday was a bit thin to hold but we could still see more accumulation through next week. Whenever we do get the news may just be what we need to leave some in the dust.
Going to the moon very shortly. Watch and learn
My money is on 50.00. Good luck with the .02 trades. LMAO
Good points. I have stated earlier that I think PASI 75 rate will be over 25 % i.e. good enough. I based that on earlier results and on eyeballing approximately what kind of changes in PASI score are required for two point drop in IGA score. Figure 1 in this publication helped in eye-balling part :)
This PIG is going down. just look at March 2017. The same scenario is happening
1.04 X 1.05 back to where we started this morning. Well, at least 500k traded so maybe Aspire/Aruda are lighter in their pockets.
my money is on 1.05 OR UNDER. $1.10 was too strong like I predicted. This pig is closing red thanks to aspire
This is true unless results are so good no one sells.
$1.10-$1.12 would be convincing for sure, but I don't see it.
If they can't even hold a week, then they are clearly going to sell off after the news. Then it really doesn't matter when they sell. They won't be the ones to take this to the levels we want.
"Vitality shows in not only the ability to persist but the ability to start over." - F_Scott_Fitzgerald
P being labeled the "riskiest" drug among our 3 is like taking three Triple Crown winners and saying which is the "riskiest" as to quality. They all are super drugs and super horses, but some go beyond even that term to super-duper and that IMO more defines Kevetrin and Brilacidin.
If P is our riskiest drug, I will take that gladly to the bank.
IMO the great divide on this board is between those that talk about P as being either everything or nothing whereas the other side believes it will be at worst better than anything currently available when all factors are considered. I say this as even though the efficacy may lag behind biologics, the safety and cost issues should propel it ahead of them as being the first recommended by doctors and should it fail, then have the patient proceed onto the higher priced/ riskier as to safety biologic products.
Saying it only has to match Otezla is a slap in the face to Prurisol as it was already beating Otezla in the 200 arm as I believe was pointed out previously.
Lets hope it's a stronger base than the previous 5 attempts to hold a dollar going back to 2016.
Need the BULLS to step in to get a 1.08 close. Hopefully the Patrick Cox buyers won’t lose patience before Monday or Tuesday.
My post from 12/1 is below. Looks like $1.08 may hold for now. Those of you that would like to take a chance might get a dime by late tomorrow. Monday could be the news, but I don't think Leo would do good news on a Friday.
12/1 Post:
"IMO the first price target (this time) is $.85, followed by $1.08. If the sp falters on the way to those targets, it may be best to sell and re-enter. This has been shown to be the case several times this year.
Pick your targets, watch the key measures, and don't get emotional about it. Easier said than done."
Not directionless. Base building after a run up.
Kinda looks to me like step, step, step, pop, hold so far. Time for the closing 40minutes to speak.
5day 5minute chart
http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=ipix&time=3&startdate=1%2F4%2F1999&enddate=4%2F25%2F2017&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=3%2C8%2C20&uf=32&lf=268435456&lf2=2&lf3=4&type=4&style=380&size=4&x=25&y=13&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11
AA is possible, but only with exceptional results. I don't know if those are coming (yes, I am hoping, but ...). The thing is, decently significant results are enough for me, because I think that IPIX is planning to license brilacidin out (at least for some indications) in order to fund the remaining and future pipeline.
I guess I was not clear enough. I think AA requires exceptional results. I did not say that exceptional results are forthcoming.
Without seeing the trial protocol it is impossible to say if interim analysis was actually included. I wonder why would they need one.
The trial is a smallish and time limited (subject in and out in 16 weeks) - not like some cancer trials where small number of responders may keep the target event count out of reach for years. Also, the trial is not addressing imminently life threatening condition when early detection of futility is not only monetary but ethical question.
But then, IPIX keeps including anticipated interim results in their press releases at least until May 2017. I don't get it. I would like to hear Leo's definition of interim results. Interim results = preliminary analysis (?) of full data set ? Final results come out after dealing with outliers? I Just don't get it. But that is no news around where I am living.
Couple small gaps to fill before news. Nothing to sweat though. 1.40s soon.
Directionless afternoon. 1.05 to 1.08 who will prevail?
Followers
|
976
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
402948
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |